Roshni Abee Patel1, Glenn T Stebbins1, Ekta B Kishen1, Brandon Barton1. 1. Department of Neurological Sciences (RAP, GTS, BB), Rush University Medical Center, Chicago, IL; Bioinformatics and Biostatistics Core (EBK), Rush University Medical Center, Chicago, IL; and Neurology Service (BB), Jesse Brown Veterans Affairs Medical Center, Chicago, IL.
Abstract
Background and Objectives: COVID-19 outcomes in patients with neurodegenerative disorders (NDs) are not well understood, and we hypothesize that there may be increased morbidity and mortality in this group. Methods: This was a retrospective cohort study performed at 3 hospitals in the Chicagoland area. All patients hospitalized with COVID-19 infection with ND during a 3-month period (March 15, 2020-June 15, 2020) were included and compared with age-matched controls (CL) at 1:1 ratio. Primary outcomes were death, intensive care unit (ICU) admission, and invasive ventilation. Secondary outcomes included presenting COVID-19 symptoms, development of encephalopathy, supplementary oxygen use, discharge disposition, and risk factors for mortality. Results: The study included 132 patients with neurodegenerative disorders and 132 age-matched CL. Ninety-day mortality (ND 19.7% vs CL 23.5%, p = 0.45) and ICU admission (ND 31.5% vs CL 35.9%, p = 0.43) rates were not significantly different between the 2 groups. Patients with ND had a lower rate of invasive ventilation (ND 11.4% vs CL 23.2%, p = 0.0075) and supplementary oxygen use (ND 83.2% vs CL 95.1%, p = 0.0012). Patients with ND were also more likely to have altered mental status or confusion as their presenting COVID-19 symptom and less likely to present with respiratory symptoms. Patients with ND were discharged to nursing home or hospice at higher rates compared with CL. Discussion: We found that there was no difference in short-term mortality of patients with ND hospitalized for COVID-19 compared with CL, but they may have higher rates of neurologic complications and disability. Future studies should address long-term outcomes.
Background and Objectives: COVID-19 outcomes in patients with neurodegenerative disorders (NDs) are not well understood, and we hypothesize that there may be increased morbidity and mortality in this group. Methods: This was a retrospective cohort study performed at 3 hospitals in the Chicagoland area. All patients hospitalized with COVID-19 infection with ND during a 3-month period (March 15, 2020-June 15, 2020) were included and compared with age-matched controls (CL) at 1:1 ratio. Primary outcomes were death, intensive care unit (ICU) admission, and invasive ventilation. Secondary outcomes included presenting COVID-19 symptoms, development of encephalopathy, supplementary oxygen use, discharge disposition, and risk factors for mortality. Results: The study included 132 patients with neurodegenerative disorders and 132 age-matched CL. Ninety-day mortality (ND 19.7% vs CL 23.5%, p = 0.45) and ICU admission (ND 31.5% vs CL 35.9%, p = 0.43) rates were not significantly different between the 2 groups. Patients with ND had a lower rate of invasive ventilation (ND 11.4% vs CL 23.2%, p = 0.0075) and supplementary oxygen use (ND 83.2% vs CL 95.1%, p = 0.0012). Patients with ND were also more likely to have altered mental status or confusion as their presenting COVID-19 symptom and less likely to present with respiratory symptoms. Patients with ND were discharged to nursing home or hospice at higher rates compared with CL. Discussion: We found that there was no difference in short-term mortality of patients with ND hospitalized for COVID-19 compared with CL, but they may have higher rates of neurologic complications and disability. Future studies should address long-term outcomes.
Authors: J A Reyes-Bueno; N Mena-Vázquez; T Ojea-Ortega; M M Gonzalez-Sotomayor; P Cabezudo-Garcia; N L Ciano-Petersen; G Pons-Pons; M V Castro-Sánchez; P J Serrano-Castro Journal: Neurologia (Engl Ed) Date: 2020-07-28
Authors: Christopher T Rentsch; Farah Kidwai-Khan; Janet P Tate; Lesley S Park; Joseph T King; Melissa Skanderson; Ronald G Hauser; Anna Schultze; Christopher I Jarvis; Mark Holodniy; Vincent Lo Re; Kathleen M Akgün; Kristina Crothers; Tamar H Taddei; Matthew S Freiberg; Amy C Justice Journal: PLoS Med Date: 2020-09-22 Impact factor: 11.069
Authors: Maura Kennedy; Benjamin K I Helfand; Ray Yun Gou; Sarah L Gartaganis; Margaret Webb; J Michelle Moccia; Stacey N Bruursema; Belinda Dokic; Brigid McCulloch; Hope Ring; Justin D Margolin; Ellen Zhang; Robert Anderson; Rhonda L Babine; Tammy Hshieh; Ambrose H Wong; R Andrew Taylor; Kathleen Davenport; Brittni Teresi; Tamara G Fong; Sharon K Inouye Journal: JAMA Netw Open Date: 2020-11-02